Perspectives in therapeutic innovation in ocular surface disorders and dry eye syndrome

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 3, Issue 3, 2009, Pages 194-199

  Cade Jorge, Fabiano ^a   Jorge, Italo Cade ^a   Kusabara, Alessandra A ^a   Rocha, Eduardo M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dry eye; Ocular surface; Patents; Technological innovation

Indexed keywords

ARACHIDONIC ACID; ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; LACTOFERRIN; LUBRICATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; PEPTIDE HORMONE; PLASMINOGEN ACTIVATOR; SEROTONIN AGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANALYZER; ARTICLE; BIOTECHNOLOGY; CONTACT LENS; DRY EYE; EYE DISEASE; EYE INFLAMMATION; GEOGRAPHIC DISTRIBUTION; HUMAN; KERATOPROSTHESIS; LOW LEVEL LASER THERAPY; OCULAR SURFACE DISEASE; PATENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPECTACLES; SYMPTOMATOLOGY; TEAR FILM; TONOMETRY;

EID: 70349193391     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221409789104782     Document Type: Article

References (41)

1. Caffery BE, Richter D, Simpson T, Fonn D, Doughty M, Gordon KC. The Canadian dry eye epidemiology study. Adv Exp Med Biol 1998; 438: 805-806.
2. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000; 118:1264-1268.
3. Lee AJ, Lee J, Saw SM, et al. Prevalence and risk factors associated with dry eye symptoms: A population based study in Indonesia. Br J Ophthalmol 2002; 86: 1347-1351.
4. Dalzell MD. Dry eye: Prevalence, utilization, and economic implications. Manag Care 2003; 12: 9-13.
5. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003; 136: 318-326.
6. Ellwein LB, Urato CJ. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 2002; 120: 804-811.
7. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: A conceptual framework and preliminary assessment. Cornea 2004; 23: 751-761.
8. Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in non-insulin-dependent diabetes mellitus. Ophthalmology 2001; 108: 586-592.
9. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 2002a; 966: 211-222.
10. Alves M, Dias AC, Rocha EM. Dry eye in childhood: Epidemiological and clinical aspects. Ocul Surf 2008; 6: 44-51.
11. Rocha EM, Alves M, Rios JD, Dartt DA. The aging lacrimal gland: Changes in structure and function. Ocul Surf 2008; 6: 162-174.
12. Saragas S, Arffa R, Rabin B, Kronish J, Miller D, Mayman C. Reversal of wound strength retardation by addition of insulin to corticosteroid therapy. Ann Ophthalmol 1985; 17: 428-430.
13. Pillion DJ, Bartlett JD, Meezan E, Yang M, Crain RJ, Grizzle WE. Systemic absorption of insulin delivered topically to the rat eye. Invest Ophthalmol Vis Sci 1991; 32: 3021-3027.
14. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 2004; 78: 409-416.
15. Yokoi N, Komuro A. Non-invasive methods of assessing the tear film. Exp Eye Res 2004; 78: 399-407.
16. Rieger G. The importance of the precorneal tear film for the quality of optical imaging. Br J Ophthalmol 1992; 76: 157-158.
17. Goto E, Yagi Y, Matsumoto Y, Tsubota K. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol 2002; 133:181-186.
18. Montes-Mico R. Role of the tear film in the optical quality of the human eye. J Cataract Refract Surg 2007; 33:1631-1635.
19. Schwebel, M. L.: US20080200885 (2008).
20. Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. Clao J 1995; 21: 221-232.
21. The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf 2007a; 5: 75-92.
22. The epidemiology of dry eye disease: Report of the epidemiology subcommittee of the international dry eye workshop. Ocul Surf 2007b; 5: 93-107.
23. Moss SE, Klein R, Klein BE. Incidence of dry eye in an older population. Arch Ophthalmol 2004; 122: 369-373.
24. Sullivan RM, Cermak JM, Papas AS, Dana MR, Sullivan DA. Economic and quality of life impact of dry eye symptoms in women with Sjogren's syndrome. Adv Exp Med Biol 2002b; 506: 1183-1188.
25. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients' lives: Comparisons to a US normative sample. Invest Ophthalmol Vis Sci 2005; 46: 46-50.
26. Monge-Najera J, Nielsen V. The countries and languages that dominate biological research at the beginning of the 21st century. Rev Biol Trop 2005; 53: 283-294.
27. Zorzetto R, Razzouk D, Dubugras MT, et al. The scientific production in health and biological sciences of the top 20 Brazilian universities. Braz J Med Biol Res 2006; 39: 1513-1520.
28. Sullivan, B.D.: WO2004017050 (2004).
29. Korb, D.R., Brancewicz, C.J.: US20090068237A1 (2009).
30. Ousler, G.W., Chapin, M.J., Abelson, M.B.: US20090010850 (2009).
31. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007; 448: 645-646.
32. Novack G. Recent news and patent approvals. Ocul Surf 2004; 2: 213-214.
33. Novack GD. Pharmacologic treatments for dry eye: A worthwhile investment? Cornea 2002; 21: 4-5.
34. Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev 2004; 3: 673-683.
35. Ellwein LB, Kroll P, Narin F. Linkage between research sponsorship and patented eye-care technology. Invest Ophthalmol Vis Sci 1996; 37: 2495-2503.
36. Ho VH, Schwab IR. Social economic development in the prevention of global blindness. Br J Ophthalmol 2001; 85: 653-657.
37. Frick KD, Foster A. The magnitude and cost of global blindness: An increasing problem that can be alleviated. Am J Ophthalmol 2003; 135: 471-476.
38. Brown MM, Brown GC, Brown HC, Peet J, Roth Z. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 2009; 127: 146-152.
39. Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjogren's syndrome. Rheumatology (Oxford, England) 2007; 46: 1389-1396.
40. Tsubota K, Toda I, Saito H, Shinozaki N, Shimazaki J. Reconstruction of the corneal epithelium by limbal allograft transplantation for severe ocular surface disorders. Ophthalmology 1995; 102: 1486-1496.
41. Gomes JA, Santos MS, Ventura AS, Donato WB, Cunha MC, Hofling-Lima AL. Amniotic membrane with living related corneal limbal/conjunctival allograft for ocular surface reconstruction in Stevens-Johnson syndrome. Arch Ophthalmol 2003; 121: 1369-1374.